Last mentioned: Mar 25, 2026
Expected Closing
Anticipated completion of the acquisition following regulatory reviews.
Keytruda Patent Cliff
Merck faces the loss of exclusivity for its top-selling cancer immunotherapy.
Interim Analysis
Expected interim efficacy data from the larger global patient cohort.
Data Evaluation
Expected first review of screening efficacy and treatment referral rates in Scotland.
Acquisition Announcement
Merck announces definitive agreement to buy Terns for $6.7 billion.
Official Rollout
Scotland officially begins screening all newborns for the rare muscle disease.
Primary Objectives Met
Announcement that Part 1 successfully validated safety and dosimetry profiles.
FY 2025 Earnings
Legend Biotech reports full-year financial results and 2026 strategic outlook.
Novartis Settlement
Novartis resolves its legal dispute with the estate over the commercial use of HeLa cells.
Scottish Policy Review
Scottish health officials evaluate the feasibility of independent implementation.
Enrollment Milestone
Completion of patient enrollment for the Part 1 SELECT lead-in phase.
Pipeline Update
Initial Phase 1 data released for solid tumor candidates in neuroendocrine carcinoma.
Manufacturing Milestone
Ghent facility reaches full operational capacity for commercial production.
Label Expansion
Carvykti receives FDA approval for earlier lines of multiple myeloma treatment.
Study Initiation
Launch of the ProstACT Global Phase 3 study for mCRPC.
Clinical Progress
Terns Pharmaceuticals advances TERN-701 through early-stage clinical trials for CML.
Clinical Advocacy
Intense campaigning by rare disease groups for the inclusion of SMA in UK-wide screening.
Thermo Fisher Settlement
A landmark confidential settlement is reached, setting a precedent for the industry.
First Major Lawsuit
The Lacks estate files suit against Thermo Fisher Scientific on the 70th anniversary of her death.
HeLa Immortality
Researchers discover the cells can reproduce indefinitely, creating the first immortal human cell line.
Merck has reached a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising Phase 2 leukemia treatment. The cash deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
Scotland has officially become the first nation in the United Kingdom to implement routine newborn screening for a rare genetic muscle disease. This landmark policy shift aims to identify affected infants at birth, allowing for immediate intervention and treatment before the onset of irreversible physical symptoms.
Legend Biotech (LEGN) has released its full-year 2025 financial results, showcasing significant revenue growth driven by the continued commercial expansion of its lead CAR-T therapy, Carvykti. The company highlighted major manufacturing milestones and a strategic pivot toward solid tumor indications following a year of intensive market penetration in earlier lines of multiple myeloma treatment.
Telix Pharmaceuticals has successfully met the primary objectives for Part 1 of its global Phase 3 ProstACT study, validating the safety and dosimetry of its lead therapeutic candidate, TLX591. This milestone de-risks the antibody-based radiopharmaceutical program and clears the path for the trial's continued expansion in metastatic castration-resistant prostate cancer.
Voyager Technologies and Zevra Therapeutics are set to report Q4 2025 earnings, highlighting a critical juncture for gene therapy delivery and rare disease commercialization. Investors are prioritizing updates on the TRACER platform milestones and the market penetration of newly launched orphan drugs.
Novartis has reached a confidential settlement with the estate of Henrietta Lacks, resolving claims that the pharmaceutical giant unjustly profited from her 'immortal' cell line. This agreement marks a major milestone in the ongoing legal and ethical reckoning over the historical exploitation of Black patients in medical research.
Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter results for the 2025 fiscal year, balancing immediate commercial headwinds with aggressive long-term guidance. Both companies introduced fiscal year 2026 outlooks, signaling a strategic shift toward post-2025 growth catalysts and pipeline diversification.
This page surfaces every story mentioning Novartis across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Novartis was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |